Bile acids are synthesized from cholesterol in hepatocytes and secreted through the biliary tract into the small intestine, where they aid in absorption of lipids and fat-soluble vitamins. Through a process known as enterohepatic recirculation, more than 90% of secreted bile acids are then retrieved from the intestine and returned to the liver for resecretion 1 . In humans, there are two Na 1 -dependent bile acid transporters involved in enterohepatic recirculation, the Na 1taurocholate co-transporting polypeptide (NTCP; also known as SLC10A1) expressed in hepatocytes, and the apical sodium-dependent bile acid transporter (ASBT; also known as SLC10A2) expressed on enterocytes in the terminal ileum 2 . In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption 3,4 . However, a lack of three-dimensional structures of bile acid transporters hampers our ability to understand the molecular mechanisms of substrate selectivity and transport, and to interpret the wealth of existing functional data 2,5-8 . The crystal structure of an ASBT homologue from Neisseria meningitidis (ASBT NM ) in detergent was reported recently 9 , showing the protein in an inward-open conformation bound to two Na 1 and a taurocholic acid. However, the structural changes that bring bile acid and Na 1 across the membrane are difficult to infer from a single structure. To understand the structural changes associated with the coupled transport of Na 1 and bile acids, here we solved two structures of an ASBT homologue from Yersinia frederiksenii (ASBT Yf ) in a lipid environment, which reveal that a large rigid-body rotation of a substrate-binding domain gives the conserved 'crossover' region, where two discontinuous helices cross each other, alternating accessibility from either side of the cell membrane. This result has implications for the location and orientation of the bile acid during transport, as well as for the translocation pathway for Na 1 .
Bile acids are synthesized from cholesterol in hepatocytes and secreted through the biliary tract into the small intestine, where they aid in absorption of lipids and fat-soluble vitamins. Through a process known as enterohepatic recirculation, more than 90% of secreted bile acids are then retrieved from the intestine and returned to the liver for resecretion 1 . In humans, there are two Na 1 -dependent bile acid transporters involved in enterohepatic recirculation, the Na 1taurocholate co-transporting polypeptide (NTCP; also known as SLC10A1) expressed in hepatocytes, and the apical sodium-dependent bile acid transporter (ASBT; also known as SLC10A2) expressed on enterocytes in the terminal ileum 2 . In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption 3,4 . However, a lack of three-dimensional structures of bile acid transporters hampers our ability to understand the molecular mechanisms of substrate selectivity and transport, and to interpret the wealth of existing functional data 2,5-8 . The crystal structure of an ASBT homologue from Neisseria meningitidis (ASBT NM ) in detergent was reported recently 9 , showing the protein in an inward-open conformation bound to two Na 1 and a taurocholic acid. However, the structural changes that bring bile acid and Na 1 across the membrane are difficult to infer from a single structure. To understand the structural changes associated with the coupled transport of Na 1 and bile acids, here we solved two structures of an ASBT homologue from Yersinia frederiksenii (ASBT Yf ) in a lipid environment, which reveal that a large rigid-body rotation of a substrate-binding domain gives the conserved 'crossover' region, where two discontinuous helices cross each other, alternating accessibility from either side of the cell membrane. This result has implications for the location and orientation of the bile acid during transport, as well as for the translocation pathway for Na 1 .
Purified ASBT Yf , when reconstituted into liposomes, mediates Na 1dependent transport of the conjugated bile acid taurocholic acid (TCA) with an apparent Michaelis constant (K m ) of 46. 8 6 7 .4 mM (Fig. 1a, b and Extended Data Fig. 1 ). ASBT Yf was crystallized in lipidic cubic phase (LCP), and the structure solved to 1.95 Å (Extended Data Table 1) . ASBT Yf has ten transmembrane segments (TM1-10) divided into two domains: a panel domain, formed by TM1, 2, 6 and 7; and a core domain, formed by TM3-5 and 8-10. The first and last five transmembrane helices are structurally homologous, and due to their respective inverted topology give ASBT Yf an internal two-fold pseudosymmetry axis ( Fig. 1c and Extended Data Fig. 2 ). In the core domain, TM4 and 9 unwind in the middle of the membrane and cross each other (Fig. 1d ), a structural motif also observed in ASBT NM . In addition to the transmembrane helices, there are four amphipathic helices, AH1-4 (Extended Data Fig. 2) , that are probably located at the interface between the membrane and the bulk solution, and can be used to infer the approximate position of the lipid bilayer. ASBT Yf assumes an inward-open conformation in which the panel and the core domains contact at the extracellular side, creating a large cavity solvent accessible only from the cytoplasm that extends as far as the crossover region ( Fig. 1d ).
In the structure of ASBT NM , which has roughly 40% sequence identity with ASBT Yf , two Na 1 -binding sites were identified, Na1 and Na2, which are both located in the core domain behind the crossover ( Fig. 1d and Extended Data Fig. 3a, b ). Na2 sits directly between the carboxy (C)terminal ends of helices TM4a and TM9a; Na1 is positioned roughly 8 Å away between TM4b, TM9a and TM5. The residues coordinating Na 1 are highly conserved between ASBT NM and ASBT Yf (Extended Data Fig. 4 ), but there is no obvious electron density at Na1 in the ASBT Yf structure that could be attributed to Na 1 , and a very weak density at Na2 (Extended Data Fig. 3c, d) . A closer examination of the residues forming the putative Na 1 -binding sites in ASBT Yf showed that they are not in a position to coordinate Na 1 optimally, probably due to a conformational change of TM4b. Whereas other transmembrane helices in the core domain of ASBT Yf align closely with those of ASBT NM , TM4b tilts ,11u away from the crossover, and its first helix turn unwinds ( Fig. 1e) . These changes bring Asn 109 and Ser 108 out of range for coordination of Na 1 in Na1, and may also affect the orientation of backbone carbonyls that form part of Na2 ( Fig. 1d and Extended Data Fig. 5a, b ). To test whether ASBT Yf contains two Na 1 -binding sites, like ASBT NM , we measured 22 Na 1 binding by purified ASBT Yf (Fig. 1f ). Wild-type ASBT Yf bound 22 Na 1 with an apparent half-maximum effective concentration (EC 50 ) of 5.37 6 0.01 mM and a Hill coefficient of 1.56 6 0.06, suggesting cooperative binding between more than one Na 1 -binding site. Consistent with the notion that Na1 and Na2 are two Na 1 -binding sites in ASBT Yf , replacing Glu 254 in Na1 or Gln 258 in Na2 with Ala reduced binding of 22 Na 1 to 49% and 68% when compared with wild-type ASBT Yf , respectively, and reduced the Hill coefficients to 1.06 6 0.02 and 0.5 6 0.1. The structure of ASBT Yf thus represents an inward-facing unliganded state lacking Na 1 and bile acid. Interestingly, the rotation of TM4b also renders Na1 accessible to the solvent from the intracellular side (Extended Data Fig. 5c, d) , presenting a potential pathway for release of Na 1 into the cytosol.
To obtain ASBT Yf in an alternative conformation, we perturbed Na1 by mutating the highly conserved Glu 254 to Ala. Although ASBT Yf (E254A) is still capable of mediating Na 1 -dependent transport (Extended Data Fig. 1c-e ), the rate of TCA uptake is substantially reduced. Like wildtype ASBT Yf , the E254A mutant was crystallized in LCP, and a complete data set was collected to 2.5 Å resolution. Interestingly, molecular replacement using the full structure of wild-type ASBT Yf as a search model did not yield a valid solution. However, when the panel and core domain were used as two independent rigid bodies, a single solution was obtained ( Fig. 2a and Extended Data Table 1 ). The core and panel domains from ASBT Yf (E254A) individually align well with those of the wild type, with a-carbon root mean squared deviation (r.m.s.d.) values of 0.9 and 1.7 Å respectively, compared with an r.m.s.d. of 3.7 Å after aligning both domains. This indicates that there is relative motion between the core and panel domains. As the amphipathic helices in the panel domain probably remain at the membrane-solvent interfaces (Extended Data Fig. 6 ), the core domain in the E254A mutant must undergo a rigid-body rotation, causing residues on TM4b and TM9b lining the interface with the panel domain to translate 6-9 Å towards the periplasm ( Fig. 2a and Supplementary Video 1). This motion is facilitated by small changes in AH2, AH4 and the TM5-6 loop, which act as hinges; a kink also forms in TM1 at Pro 10. Whereas in the wildtype structure, the cavity between the two domains is sealed on the extracellular side by interactions between TM9b, TM2 and TM7, in the E254A structure the two domains now form contacts between TM4b, TM2 and TM7 at the intracellular side. This creates a deep cavity allowing solvent access to the crossover region from the extracellular side ( Fig. 2b) . Similarly to the wild-type ASBT Yf structure, the E254A structure is not bound to Na 1 or a bile acid, and thus, the structure of E254A is probably in the outward-open unliganded conformation.
To address the question of how this rigid-body motion of the core domain can translocate bile acid across the membrane, we compared the solvent-accessible surfaces of the inward-and outward-facing cavities in the two structures. This analysis reveals a narrow area running across the centre of the core and panel domains that is accessible to the solvent in both the inward-open and outward-open conformations (Fig. 2c ). The dual-accessibility region includes the crossover region, and contains residues that are highly conserved among ASBT homologues. To test whether the crossover region is indeed accessible from the periplasm, as predicted by the E254A structure, and that the outward-open conformation is not simply an artefact caused by detergent solubilization and/or mutation to Na1, we measured the accessibility of introduced cysteines in the domain interface to modification by a membrane-impermeable pegylating reagent either from the periplasm of intact Escherichia coli cells, or from both sides of the membrane in cells ruptured by sonication ( Fig. 2d, e ). The cysteine mutants were still able to transport TCA, albeit at a reduced rate, indicating that they probably undergo similar conformational changes as wild-type ASBT Yf (Extended Data Fig. 7a ). All three mutants were pegylated when exposed to the reagent in ruptured cells, but the cysteine at position 123, which is accessible only from the intracellular side in both conformations, was not pegylated in intact cells. Despite being inaccessible to the periplasm in the wild-type structure, the T106C mutation located near the crossover was pegylated in intact cells, suggesting that the crossover region is indeed accessible from the extracellular side, as observed in the E254A structure.
In the ASBT NM structure, a TCA was built into the inward-facing cavity with an orientation roughly perpendicular to the membrane, that is, with the cholesterol ring close to the crossover and the taurine group extending to the intracellular entrance of the cavity. Curiously, most of the residues forming the TCA-binding site in the ASBT NM structure are accessible only in the inward-open state (Fig. 2c ). In the outward-open state, this TCA-binding site is buried in the protein matrix without an access pathway from the periplasm. This observation seems at odds with the alternating-access model 10, 11 , according to which ligand is transported across the membrane via the alternating exposure of central ligand-binding sites to the intracellular or the extracellular space through a sequence of distinct conformational alterations. Structural validation of the principles of the alternating-access mechanism has been obtained from crystal structures of several transporters [12] [13] [14] [15] [16] [17] [18] [19] [20] . One possible resolution T1   T1   T2   T2   T2   T7   T7   T7   T10   T10   T5   T9   T9   T4   T4   T8   T8   T3   T3   T1   T6 
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for this apparent conflict is that the transporter possesses another as yet unobserved binding site for TCA, which, unlike the binding site shown in ASBT NM , has alternating access to both the periplasm and cytoplasm. For example, the bile acid could bind in a lateral orientation to the dual-access region described earlier (Extended Data Fig. 7c ), with its mostly hydrophobic b-face oriented towards the hydrophobic panel domain, and its hydrophilic a-face close to polar residues on the core domain (Extended Data Fig. 7d ). In this configuration, the rigidbody motion of the core domain revealed by the two ASBT Yf structures would be sufficient to translocate the bile acid across the membrane. Mutation of polar residues capable of forming hydrogen bonds to the three hydroxyls on the steroid nucleus of TCA in a speculative horizontal orientation reduces TCA binding relative to wild-type ASBT Yf (Extended Data Fig. 7e , f ). However, introducing mutations to the protein can affect substrate binding in detergent indirectly through a variety of mechanisms not involving direct contact with the substrate, and further experimental validation will be required to demonstrate the existence of a horizontal binding site in ASBT. Experimental observation of distinct conformations of secondary transporters during the transport cycle is a major challenge in understanding the transport-associated dynamics of these molecular machines. We have presented two alternative conformations of a transporter, produced by a point mutation in a Na 1 site. It cannot be fully excluded that mutating Na1 resulted in perturbations from the native structure, but the two structures appear to correspond to ligand-free inward-and outward-open states. To investigate further the states of the ASBT transport cycle, we measured the interdependency of Na 1 and TCA binding with the scintillation proximity assay (SPA). Binding of TCA to ASBT Yf is strongly dependent on the concentration of Na 1 (Fig. 3a) , whereas TCA has a minimal effect on Na 1 binding (Fig. 3b ). This suggests that the Na 1 sites are occupied before TCA can bind to the transporter. From these results, we can begin to enumerate and order conformational states in a preliminary model of the ASBT transport cycle (Fig. 3c ).
ASBT Yf and ASBT NM share their fold with NhaA (a member of the Na 1 /H 1 antiporter family). NhaA also possesses inverted psuedosymmetry repeats that form a substrate-binding core domain and a panel domain, although the panel domain typically contains two or more additional helices that form a homodimer interface 21 (Extended Data Fig. 8a ). Two Na 1 /H 1 antiporter structures (NhaA and NapA) have been published 21, 22 , which correspond to inward-open and outward-open states. Despite the substantial difference in the size of the substrates involved, the rigid-body movement of the core domain that converts between the two states in the Na 1 /H 1 antiporters is remarkably similar to that observed for ASBT Yf (Extended Data Fig. 8b , c). As in ASBT Yf , the conformational change provides alternating access to the crossover region, where Na 1 and protons are predicted to bind to a cluster of conserved acidic residues. However, this site is not equivalent to either Na1 or Na2 in the bile acid transporter. Examination of the site on NapA corresponding to Na2 shows that two of the polar residues coordinating Na 1 in ASBT Yf (Gln 258 and His 71; Extended Data Fig. 8f ) are in fact replaced with two positively charged side chains (Arg 331 and Lys 305; Extended Data Fig. 8g ), which form hydrogen bonds with the C-terminal ends of helices TM4a and TM11a (TM4a and TM9a in ASBT Yf ). In the structurally unrelated antiporter CaiT, which is Na 1 independent, an arginine residue has recently been shown to mimic binding of Na 1 to a site found in Na 1 -dependent symporters of the same fold 23 . It might therefore be LETTER RESEARCH feasible to speculate that these residues in NapA can have a role analogous to bound Na 1 in ASBT Yf and ASBT NM . Further comparison of these two families of transporters may provide insight into how the same fold and conformational change can act as 'scaffolding' for highly distinct substrates and coupling mechanisms. The ASBT Yf structure also shows some interesting parallels with structurally unrelated families of transporters. For example, the translation towards the periplasm observed in ASBT Yf (E254A) is similar to the elevator-like motion of the substrate-binding domain in Glt Ph , a homologue of the glutamate transporter 17, 24 (Extended Data Fig. 8d ).
Although they belong to an unrelated fold, the structures of ASBT Yf invite comparison to recent structures obtained for E. coli XylE, a xylose/H 1 symporter belonging to the major facilitator superfamily (MFS) with homology to the mammalian GLUT transporters. Like the bile acid transporters, MFS transporters contain two domains, with a substratebinding site located at the domain interface, and also possess inverted pseudosymmetry repeats. However, whereas in the bile acid transporter fold helices from each repeat are interleaved between the asymmetric panel and core domains, in the MFS fold each of the two pseudosymmetry repeats forms a separate six-helix domain. Recently, structures of XylE from E. coli have been solved in the inward-and outward-facing conformations, as well as a potential intermediate conformation 15, 18 (Extended Data Fig. 8e ). Comparison of the three states shows that, like ASBT Yf , XylE provides alternating access to the central substrate-binding site by the rigid-body motion of a mobile domain relative to a fixed domain, although in XylE the conformational change is largely a rocking motion that does not translate the binding site towards the opposite side of the bilayer.
In XylE, salt bridges between conserved residues in the two domains have been proposed to have a key role in conversion between the inwardand outward-open conformations 15 . In contrast, in ASBT Yf there are few hydrophilic interactions between polar or charged residues on the core domain and the very hydrophobic panel domain, a feature that may lower the energy barrier to moving the two domains relative to each other. Regardless, in both structural folds, even with multiple conformations of the same transporter, it is still not obvious how binding of Na 1 or H 1 and the cognate substrate could trigger a conversion between the two alternate conformations. Further studies are necessary to understand how the energy from Na 1 or H 1 binding triggers and drives the conformational changes required for binding and translocation of the cognate substrate.
In humans, ASBT inhibitors have received considerable attention as potential therapeutics for the treatment of hypercholesterolaemia 25 and type 2 diabetes 26 . Another possible medical application of compounds targeting bile acid transporters involves conjugating bile acids to drugs with poor oral bioavailability, so that they are recognized as substrates by ASBT and NTCP and absorbed in the intestine and liver 27 . Both approaches would greatly benefit from an improved understanding of bile acid transporter structure and mechanism of action. ASBT Yf shares 22% sequence identity and 59% similarity with human ASBT. Additionally, the residues forming the two Na 1 -binding sites are highly conserved (Extended Data Fig. 4 ). This suggests that the overall fold and transport mechanism are similar between the two proteins, and that ASBT Yf may serve as a useful model system for understanding mechanisms of transport and inhibition in the mammalian ASBT homologues.
METHODS SUMMARY
The gene encoding ASBT Yf (RefSeq accession ZP_04633709.1) was obtained by PCR from the genomic DNA of Y. frederiksenii, ligated into a modified pET vector, and expressed in E. coli. The ASBT Yf protein was extracted from the cell membrane, purified by a metal affinity column, and further purified by size-exclusion chromatography. Crystals were grown in LCP with 30% (v/v) PEG-400, 0.1 M Nacitrate pH 5.5, 0.1 M NaCl and 3% (w/v) D-trehalose for the wild-type protein and 39% (v/v) PEG-400, 0.1 M Tris-HCl pH 8.5, 0.1 M KCl and 10 mM MnCl 2 for the E254A mutant. The wild-type structure was solved by molecular replacement using the structure of ASBT NM (PDB accession 3ZUX) as a search model; the E254A mutant was solved by molecular replacement with the separate core and panel domains of the wild-type structure. All structure figures were made in Pymol. 22 Na 1 and 3 H-TCA binding were measured with the SPA 28, 29 , and the solvent accessibility of ASBT Yf cysteine mutants was measured by modification with mPEG-Mal-5K. Uptake of 3 H-TCA into ASBT Yf -containing proteoliposomes of polar E. coli lipid extracts (Avanti) was measured with a rapid filtration assay as described previously 30 .
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. In the ligand-free state (I), corresponding to the E254A ASBT Yf structure, the crossover region is exposed to the periplasm. Na 1 then binds to Na1 and Na2 (II), facilitating the binding of TCA, probably to the dual-accessibility region (III). Conversion to the inward-open conformation (IV) allows TCA access to the binding site observed in the ASBT NM structure (V). Exposure to lower Na 1 concentrations in the cytoplasm drives release of Na 1 , possibly by the pathway opened by the rotation of TM4b in the ASBT Yf structure (VI), which in turn triggers release of TCA.
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METHODS SPA-based binding assay. Binding of radiolabelled Na 1 and TCA to His-tagged ASBT Yf was measured with the SPA 28, 29 . Cu 21 -coated polyvinyl toluene (PVT) or yttrium silicate (YSi) SPA beads were diluted to 2.5 mg ml 21 in assay buffer. For the 22 Na 1 binding experiments the assay buffer was composed of 200 mM HEPES-Tris, pH 7.5, 20% glycerol, 1 mM tris(2-carboxyethyl)phosphine (TCEP; Sigma), and 0.19% (w/v) DM (Anatrace), whereas for 3 H-TCA-binding experiments 200 mM HEPES-Tris was equimolarly replaced with 50 mM HEPES-Tris, pH 7.5 and 150 mM NaCl. Two-hundred and fifty nanograms of the indicated purified recombinant (His-tagged) ASBT Yf variants were added to 100 ml of the SPA-bead solution. Binding of 0.5 mM 3 H-TCA (10 Ci mmol 21 ; American Radiolabelled Chemicals) was measured in the presence of 0-5 mM TCA, and binding of 0.95 mM [ 22 Na]Cl (5.92 Ci mmol 21 ; Perkin Elmer) was assayed in the presence of 0-100 mM non-labelled NaCl in individual wells of clear-bottom/white-wall 96well plates. Equilibrium binding was performed in the dark for 16 h at 4 uC with vigorous shaking on a vibrating platform and the counts per minute (c.p.m.) were determined in the SPA mode of a Wallac 1450 MicroBeta plate PMT counter. The non-proximity background signal was determined for each sample in the presence of 800 mM imidazole, which prevents the interaction of the His-tagged protein with the Cu 21 -coated SPA beads, and the non-proximity c.p.m. was subtracted from the c.p.m. determined in the absence of imidazole to obtain the specific binding activity. Data were normalized with regard to the activity of wild-type ASBT Yf in the absence of non-labelled ligand and set as 100%. All experiments were performed at least in duplicate with replicas of $3 and data are expressed as mean 6 s.e.m. Data fits of kinetic analyses were performed using nonlinear regression algorithms in Prism 5 (GraphPad) and errors represent the s.e.m. of the fit. Data in Fig. 1f were fit to a dose-response curve in the form of Y~minz max{min 1z ½Na EC 50 n where n is the Hill coefficient.
Uptake of 3 H-TCA in proteoliposomes. Before reconstitution, the N-terminal His tag on cobalt-affinity-purified ASBT Yf was removed by digestion with achymotrypsin followed by gel filtration as described below for protein used for crystallization. The chymotrypsin-treated wild-type ASBT Yf and variants were reconstituted at a 1:100 (w/w) ratio in preformed, Triton X-100 (0.12% (w/w)) destabilized liposomes that were prepared of E. coli polar lipid extract (Avanti) in 100 mM potassium phosphate, pH 7.5, 2 mM b-mercaptoethanol 30 . Before the uptake measurements, frozen proteoliposomes were thawed at 23 uC and extruded through a 400 nm filter. The uptake reaction was initiated by the 20-fold dilution of the proteoliposome suspension (5 mg lipid per ml) into assay buffer composed of 10 mM HEPES, pH 7.4, 100 mM NaCl (or 100 mM choline chloride), 1 mM CaCl 2 , 1 mM MgCl 2 plus 1 mM 3 H-TCA at 37 uC. The 3 H-TCA was adjusted to a specific activity of 10 Ci mmol 21 in all uptake experiments, except for the assays in Extended Data Fig. 1c -e, where a specific activity of 20 Ci mmol 21 was used. Reactions were stopped by the addition of ice-cold 100 mM potassium phosphate, pH 6.0, 100 mM LiCl and filtered through 0.22 mm nitrocellulose filters (Millipore). The radioactivity retained on the filters was determined with scintillation counting. Known amounts of radioactivity were used to convert counts per minute to mol. Kinetic constants were determined using appropriate algorithms in GraphPad Prism 5.01 and expressed as the mean 6 s.e.m. of the fits. Data in Fig. 1b were fit to a standard Michaelis-Menten equation; data in Fig. 3a were fit to a standard Hill equation.
Cloning and expression of ASBT homologues. Bacterial homologues of human ASBT (RefSeq accession NP_000443.1) were cloned into two modified pET plasmids (Novagen), one with an N-and another with a C-terminal decahistidine tag cleavable by an engineered tobacco etch virus (TEV) protease recognition site, and examined for expression in E. coli. A total of 70 bacterial homologues were examined, and three of them produced proteins that were mono-disperse after detergent extraction. Part of the cloning and expression study was performed at the central facility of the New York Consortium on Membrane Protein Structure (NYCOMPS) 31 . Expression vectors containing the gene of interest were transformed into BL21-Gold (DE3)-competent cells (Agilent). For large-scale protein expression, transformed cells were grown in Luria-Bertani (LB) media to an optical density at 600 nm of ,1 at 37 uC. Overexpression of the protein was induced by addition of isopropyl b-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM at 20 uC overnight. Cells were harvested by centrifugation and cell pellets were resuspended in lysis solution (LS) containing 20 mM HEPES pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 2 mM b-mercaptoethanol and 1 mM phenylmethanesulfonyl fluoride (PMSF). Cells were lysed by sonication and n-dodecyl-b-D-maltopyranoside (DDM) was added to a final concentration of 30 mM. The mixture was shaken at 20 uC for 2 h and centrifuged (16,000g for 45 min) at 4 uC. The supernatant was then loaded onto a cobalt metal affinity column, washed with LS supplemented with 20 mM imidazole, and eluted with LS supplemented with 300 mM imidazole.
Crystallization. Crystallization was pursued on the three clones that produced monodispersed proteins, and the clone from Y. frederiksenii (ASBT Yf ) with an N-terminal decahistidine tag generated the best crystals. Cobalt-affinity-purified ASBT Yf was treated with a-chymotrypsin (TLCK treated; Worthington) at a 20:1 ratio (w/w, ASBT Yf :a-chymotrypsin) for 30 min at 20 uC to generate a stable core. The proteolytic reaction was stopped by addition of 1 mM PMSF, followed by concentration of the protein to ,8 mg ml 21 , which was loaded onto a Superdex 200 10/300 GL column (GE Health Sciences) equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM b-mercaptoethanol and 4 mM n-decyl-b-D-maltopyranoside (DM). The purified ASBT Yf protein was concentrated to ,50 mg ml 21 as approximated by ultraviolet absorbance and mixed with 1-oleoyl-rac-glycerol (monoolein; Sigma-Aldrich) at a 2:3 (w/w) protein-to-lipid ratio using the twin-syringe mixing method 32 . The protein/lipid mixture was dispensed manually in ,50 nl drops onto 96-well glass sandwich plates and overlaid with 1.5 ml precipitant solution per drop. The wild-type ASBT Yf crystals were grown in 30% (v/v) PEG-400, 0.1 M Na-citrate pH 5.5, 0.1 M NaCl and 3% (w/v) D-trehalose, and the ASBT Yf (E254A) crystals were grown in 39% (v/v) PEG-400, 0.1 M Tris-HCl pH 8.5, 0.1 M KCl and 10 mM MnCl 2 . The crystals reached full size within 5-7 days at 20 uC. The E254A crystals were soaked in 10 mM taurocholic acid for 2 h before harvest, and both crystals were flash frozen in liquid nitrogen without additional cryoprotectant. Data collection and structure solution. Diffraction data were collected on beamline 8.2.2 at the Advanced Light Source, on beamline X29 at the National Synchrotron Light Source and on beamlines 24ID-E and 17ID-B at the Advanced Photon Source. The data were indexed, integrated and scaled using the HKL2000 software suite. The wild-type ASBT Yf structure was solved by molecular replacement with Phaser 33 using the ASBT NM structure as a search model. The asymmetric unit contained two ASBT Yf monomers, and strong NCS restraints were used during early model building and refinement. Manual model building and refinement were carried out using Coot 34 and phenix.refine 35 , and Molprobity 36 was used to monitor and improve protein geometry. The final model contains residues 1-307 in chain A and residues 3-306 in chain B, 147 water molecules, 2 monoolein molecules and 2 molecules of citrate, which was included in the crystallization solution as a buffer, and appears to bind directly to the crossover region (Extended Data Fig. 9a, c) . To rule out the concern that the bound citrate molecules were perturbing the Na 1 -binding sites, 22 Na 1 binding in the presence/absence of 5 mM potassium citrate was measured by SPA, which showed very little effect (Extended Data Fig. 9b ). The E254A structure was solved by molecular replacement using sequential searches with the separate core and panel domains of wild-type ASBT Yf . Model building and refinement followed the same methodology as for the wild-type structure. The final asymmetric unit contained residues 1-301 of ASBT Yf (E254A) and 14 water molecules. Although the crystal was soaked in 10 mM TCA, no density consistent with TCA could be identified in the structure. Five residues from the TEV cleavage site on the N terminus are also resolved in the structure, and form a continuation of TM1.
Solvent accessibility in Fig. 2c and Extended Data Fig. 7c was visualized by selecting residues within 4 Å of spheres placed by the program HOLLOW 37 , using a probe radius of 1.4 Å . VMD 38 was used to calculate r.m.s.d. values, transformation matrices, and miscellaneous other molecular properties. Intermediate states for the morphing animation in Supplementary Video 1 were calculated using LSQMAN 39 . All structure figures were prepared in Pymol (Schrödinger, LLC). Pegylation assay. Site-directed mutagenesis was performed using the QuikChange kit (Agilent). For pegylation experiments, the native cysteines of ASBT Yf (C196 and C248) were mutated to serines before the introduction of single cysteine mutations at positions 106 (Thr), 123 (Val) or 269 (Ile). Accessibility of specific residues on ASBT Yf embedded in E. coli membranes was probed by pegylation using a membrane-impermeable pegylating reagent, methoxypolyethylene glycol maleimide 5,000 (mPEG-Mal-5K; Sigma-Aldrich). Briefly, E. coli cells expressing ASBT Yf carrying specific single cysteine mutations were harvested and washed twice with pegylation buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl and 10% (v/v) glycerol. The cells were resuspended in the pegylation buffer (50 ml culture per ml buffer) and split into four aliquots. The first is a control that did not contain any pegylation reagents; the second one was treated with 10 mM mPEG-Mal-5K at room temperature (21-23 uC) for 1 h with shaking; the third sample was sonicated first to break the cells in the presence of 10 mM mPEG-Mal-5K and then incubated at room temperature for 1 h; and the fourth sample was first treated with 20 mM NEM (2 h at room temperature) to block free cysteines and then treated with 10 mM mPEG-Mal-5K at room temperature for 1 h. The pegylation reaction was stopped by addition of b-mercaptoethanol to a final concentration of 20 mM. After pegylation, samples 1, 2 and 4 were sonicated, and DDM was added to all four samples to a concentration of 30 mM. The mixtures were then shaken at 20 uC for 2 h to extract membrane proteins, and cleared with centrifugation (40,000g, 45 min). The supernatant was then loaded onto columns packed with 0.5 ml of cobalt beads, washed with 30 bed volumes of pegylation buffer containing 20 mM imidazole pH 8, and eluted with 5 bed volumes of pegylation buffer containing 300 mM uptake into proteoliposomes reconstituted with wild-type (red) or E254A (blue) ASBT Yf , or control liposomes (black) without protein, in the presence of 100 mM external NaCl. Uptake was measured under three conditions: in intact liposomes with an inwardly directed Na 1 gradient (c); in the presence of 25 mg ml 21 of the Na 1 -selective ionophore gramicidin, collapsing the Na 1 gradient (d); and in the presence of 25 mg ml 21 gramicidin and 0.05% of the detergent n-dodecyl-b-D-maltopyranoside (e). Under the latter condition, the liposomes are permeabilized, and only 3 H-TCA bound to the lipids and protein is measured.

Extended Data Figure 7 | Accessibility of residues in the crossover region and potential substrate-binding sites. a, Empty liposomes or proteoliposomes reconstituted with 1:100 (mg:mg) wild-type, C196S/C248S/ T106C, C196S/C248S/V123C or C196S/C248S/I269C ASBT Yf were assayed for uptake of 1 mM 3 H-TCA (10 Ci mmol 21 ) in the presence of 100 mM NaCl for the indicated time periods. b, Accessibility of the T106C, V123C and I269C residues to modification by mPEG-Mal-5K, assessed by a shift in mobility on a Coomassie-blue-stained SDS-PAGE gel (same as in Fig. 2d , shown here uncropped). Each cysteine mutant was overexpressed in E. coli and subjected to four different conditions before purification: no addition of mPEG-Mal-5K; addition of mPEG-Mal-5K to the outside of whole cells; addition of mPEG-Mal-5K after sonication to rupture the cell membranes; and addition of mPEG-Mal-5K to whole cells after block of cysteines with NEM. c, The core domain of ASBT Yf , viewed from the central-cavity-facing side, with the inward accessible, outward accessible, and dual accessible surface areas coloured as in Fig. 2c . A molecule of TCA is shown modelled into two potential binding sites: left, the binding site observed in the ASBT NM structure; and right, a laterally oriented binding site based on the location of residues accessible to solution in both the inward-open and outward-open ASBT Yf crystal structures. d, Surface representations of the core and panel domains of ASBT Yf , both oriented with the cavity-facing sides in front, coloured by element. Carbon atoms are shown as blue-grey, oxygen atoms as red, nitrogens as dark blue, and sulphurs as yellow. e, Locations of polar residues near the crossover region. TCA is shown based on the ASBT NM structure (left) and accessibility in the ASBT Yf structures (right). f, Binding of 1 mM 3 H-TCA in the presence of 150 mM NaCl by wild-type and mutant ASBT Yf measured with the SPA. Mutations that reduce binding by more than 20% relative to the wild-type protein are labelled in red. Error bars are s.e.m. of triplicate measurements.
